These data suggests that the senescence-defining chromatin state induced by CDK4/6i treatment of parental breast cancer cells is reinstated when proliferating, CDK4/6i–resistant cells are treated with CDK2 inhibition. This evidence concerns the gene CDK4 and breast carcinoma.